annexin a1-derived peptide nanomedicine

Annexin A1-derived peptide nanomedicine refers to nanotechnology-enabled formulations of peptides derived from annexin A1, a protein involved in inflammation resolution and immune regulation. Specific annexin A1-derived peptides (notably A11 and Ac2–26) have been engineered into nanomedicines for targeted delivery and enhanced therapeutic effects. - **Mechanism of action:** - Peptide A11: Competitively binds to programmed cell death ligand 1 (PD-L1) on tumor cells, displacing its deubiquitinase USP7, leading to PD-L1 degradation and restoring T cell–mediated antitumor immunity in cancer. - Ac2–26 peptide: Mimics annexin A1 to activate formyl peptide receptors FPR1 and FPR2/ALX on immune cells, mediating resolution of inflammation and promoting tissue repair. - **Nanomedicine formulation:** Encapsulation in nanoparticles, such as liposomes or polymeric carriers, improves peptide stability, bioavailability, and targeted delivery to tumor or inflamed tissues for enhanced therapeutic efficacy and reduced side effects. - **Primary indications:** Cancer immunotherapy (multiple solid tumors) for peptide A11; resolution of inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) for Ac2–26 and related peptides. - **Developers:** Academic and translational research groups (e.g., Queen Mary University of London, Emory University, others cited in research articles).

Other names

annexin a1-derived peptide a11ac2–26 peptide nanomedicine